HLYK · HealthLynked Corp
$2.60
-0.05 (-1.81%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without raising additional capital, there is substantial doubt about the Company's ability to continue as a going concern through August 14, 2027.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.47M
Shares
2.95M
HLYK metrics
43 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$2.60
Market cap
$7.47M
Price action
19 metricsPrice change (1W)
+6.0%
Price change (30D)
-3.6%
Price change (3M)
-11.4%
Price change (6M)
-20.9%
Price change (YTD)
+89.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
207.3%
Beta
-0.5
RSI (14D)
46.7
Price vs SMA 50
-9.6%
Price vs SMA 200
+0.0%
Avg volume (3M)
2,049
Relative volume
0.7
Average dollar volume
$6,111
Company
3 metricsSector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
2.95M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.4×
reciprocal yield 18.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-53.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-167.6%
Trailing 12 months
Net margin
-289.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$2.30M
Net income (TTM)
−$3.97M
Trailing 12 months
Diluted EPS (TTM)
$-1.38
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-57.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.4%
Year over year · more shares
Revenue CAGR (3Y)
-29.4%
Revenue CAGR (5Y)
-19.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-249.2%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$2.22M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$12,844
Total assets
$1.59M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$1.44M
Capital expenditures (TTM)
$2,598
R&D (TTM)
—
SG&A (TTM)
$2.32M
Stock compensation (TTM)
$531,992
R&D / revenue
—
Stock compensation / revenue
38.8%
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged